DBV Technologies reported $-64.8M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amarin USD -2.26M 564K Dec/2025
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
DBV Technologies USD -64.8M 16.9M Sep/2026
Galectin Therapeutics USD -11.29M 1.64M Jun/2024
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
Incyte USD -707.47M 1.41B Sep/2026
Insmed USD -81.83M 19.48M Sep/2026
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
PTC Therapeutics USD 148.98M 103.09M Jun/2026
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
United Therapeutics USD 241.3M 89.5M Sep/2026